Irene Troupansky is the Senior Software Architect at Vivli.
Prior to joining Vivli, Irene was a Senior Software Architect at Examity where she helped the company to launch its first Cloud SaaS Multi-Tenant version of Examity Platform and lead its further design and development through the company rapid growing, insuring Examity’s leading place as online proctoring provider. Prior to Examity, Irene was a Lead Architect/Developer at Tracker Systems, where she helped the company to upgrade its product to a Cloud SaaS version and lead the product further design and development.
Marcia recently retired as a VP of Statistics at Pfizer with responsibility for clinical development in the CVMET therapeutic area and globally sponsored Pfizer’s China Research & Development Center (CRDC) Statistics organization. While at Pfizer Marcia led the global biometrics organization for Pfizer’s marketed medicines clinical research programs and established regional biometrics centers for Latin America, Europe, Asia and China. Marcia has extensive experience in the analysis and interpretation of clinical trial data across numerous therapeutic areas, particularly in Cardiovascular and Anti-infectives. She has served as the statistical leader for regulatory submissions with the responsibility of ensuring biometrics business support of the global pharmaceutical product portfolio. In addition to her role leading Statistics groups, Marcia was a member of Pfizer’s team for the clinical trial disclosure policy, and played a key leadership role in defining Pfizer policy on the issue. She was a member of Pfizer’s internal steering committee for their Bioethics Advisory Panel and a member of Pfizer’s Clinical Trials Policy Group. She is a member of the Stevens Institute Business Intelligence & Analytics Program Advisory Board, which she joined in 2012. She is a member of the ASA Committee on Professional Ethics. Marcia holds BS degrees in Mathematics and Life Sciences from MIT, an MS in Biostatistics form UNC, and an ScD in Biostatistics from Harvard University. She received a Masters in Bioethics form U Penn in 2012.
Frank has had diverse research interests and consulting experience in industry and academia including clinical trials design, data monitoring, data standards, benefit/risk, real world evidence, cardiovascular research, and, most recently, safety and pharmacovigilance. He has been a leader in the scientific community in promoting data disclosure and transparency in clinical research. Frank is a full-time Professor of Biostatistics and Bioinformatics at Duke Clinical Research Institute. He is also a Managing Partner of HunterRockhold, Inc., which provides strategic consulting to Industry, Government, and Academia in the areas of clinical trials, pharmacovigilance, data disclosure, and transparency. Frank’s 40-year career includes senior research positions at Lilly, Merck, and GlaxoSmithKline, where he recently retired as Senior Vice President of Global Clinical Safety and Pharmacovigilance. He has held faculty appointments at six different universities. Frank served for 9 years on the board of directors of the non-profit CDISC, most recently as Chairman, and is past president of the Society for Clinical Trials. He is a member of the PCORI Clinical Trials Advisory Panel and is on the board of the Frontier Science and Technology Research Foundation. Frank is widely published in major scientific journals across a wide variety of research topics. He holds a BA in Statistics from The University of Connecticut, an ScM in Biostatistics from the Johns Hopkins University, and a PhD in Biostatistics from the Medical College of Virginia. Frank is a Fellow of both the American Statistical Association and the Society for Clinical Trials and an Accredited Professional Statistician, PStat®.
